메뉴 건너뛰기




Volumn 3, Issue 1, 2004, Pages 87-96

The possibilities and pitfalls for anti-complement therapies in inflammatory diseases

Author keywords

Animal model; Complement; Complement regulator; Inflammation; Therapy

Indexed keywords

ACICLOVIR; ANAPHYLATOXIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5 ANTIBODY; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; FOSCARNET; GANCICLOVIR; NEUTRALIZING ANTIBODY; OSELTAMIVIR; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VALACICLOVIR; VIDARABINE; ZANAMIVIR; COMPLEMENT; COMPLEMENT INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

EID: 2942582222     PISSN: 1568010X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568010043483890     Document Type: Review
Times cited : (33)

References (175)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.